Based on these observations, clinical trials are currently testing the safety and efficacy of a number of FcRn‐targeting compounds (Kiessling et al., 2017) in patients with pemphigus (NCT03334058 and NCT03075904), as well as other autoantibody‐mediated diseases (NCT03075878, NCT03052751, and NCT02718716). Here, FCGRT is linked to pemphigus.